Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes
Authors:
- 1 May 2013
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 8 (3) , 229-238
Abstract
Glucagon-like peptide-1 receptor agonists have become an important therapeutic option for patients with Type 2 diabetes because of their ability to lower blood glucose and help patients lose weight. There are currently three glucagon-like peptide-1 receptor agonists on the market. In the near future, albiglutide will undergo review by the US FDA for possible approval. Results from Phase I/II trials have demonstrated that albiglutide is a safe and efficacious medication for treating Type 2 diabetes. It lowers hemoglobin A1c and decreases bodyweight. It appears to have fewer gastrointestinal side effects than liraglutide. The once-weekly (or possibly longer duration) dosing of albiglutide may improve adherence. Several Phase III trials are expected to be completed in 2013. These trials will shed further light on the safety and efficacy of albiglutide.Keywords
This publication has 44 references indexed in Scilit:
- Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic EfficiencyPLOS ONE, 2011
- An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the futureDiabetes, Obesity and Metabolism, 2011
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral AgentsDiabetes Care, 2010
- Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and BenefitsDiabetes Care, 2010
- Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?British Journal of Pharmacology, 2009
- Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion modelBMC Cardiovascular Disorders, 2009
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 DiabetesDiabetes Care, 2009
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in MiceDiabetes, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008